These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 8164949)

  • 21. [Application of multi-tumor markers in ovarian carcinoma].
    Feng J; Qian H; Tian Y
    Zhonghua Fu Chan Ke Za Zhi; 1998 May; 33(5):284-6. PubMed ID: 10682440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Increased level of carcinoembryonal antigen is not primarily a marker for ovarian cancer].
    Kristensen CA; Roed HM
    Ugeskr Laeger; 2005 Jan; 167(2):189; author reply 190. PubMed ID: 15697136
    [No Abstract]   [Full Text] [Related]  

  • 23. [Selected hematopoietic cytokines in patients with colorectal cancer].
    Mroczko B; Ławicki S; Szmitkowski M; Czygier M; Okulczyk B; Piotrowski Z
    Pol Merkur Lekarski; 2003 Nov; 15(89):416-9. PubMed ID: 14969133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic role of CA-125 nadir in stage IV epithelial ovarian cancer.
    Prat A; Parera M; Del Campo JM
    J Clin Oncol; 2008 Apr; 26(10):1771-2; author reply 1772. PubMed ID: 18375912
    [No Abstract]   [Full Text] [Related]  

  • 25. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
    Ławicki S; Szmitkowski M; Wojtukiewicz M
    Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Tumor markers in epithelial ovarian cancer].
    Di Cocco B; Calabretta F; Alghisi F; Salesi N; Bossone G
    Minerva Ginecol; 2003 Aug; 55(4):327-32. PubMed ID: 14581857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma.
    Toy EP; Chambers JT; Kacinski BM; Flick MB; Chambers SK
    Gynecol Oncol; 2001 Feb; 80(2):194-200. PubMed ID: 11161859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of combined use of macrophage colony-stimulating factor and squamous cell carcinoma antigen as a selective diagnostic marker for squamous cell carcinoma arising in mature cystic teratoma of the ovary.
    Suzuki M; Tamura N; Kobayashi H; Ohwada M; Terao T; Sato I
    Gynecol Oncol; 2000 Jun; 77(3):405-9. PubMed ID: 10831350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Tumor marker in ovarian cancer].
    Komai K; Nishida T
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):481-6. PubMed ID: 11915744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
    Moore RG; Brown AK; Miller MC; Skates S; Allard WJ; Verch T; Steinhoff M; Messerlian G; DiSilvestro P; Granai CO; Bast RC
    Gynecol Oncol; 2008 Feb; 108(2):402-8. PubMed ID: 18061248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of serum transforming growth factor-alpha in patients of primary epithelial ovarian cancers by enzyme immunoassay.
    Chien CH; Huang CC; Lin YH; Shen J; Chow SN
    Gynecol Oncol; 1997 Sep; 66(3):405-10. PubMed ID: 9299253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nerve growth factor, follicle stimulating hormone receptor and epithelial ovarian cancer.
    Bose CK
    Med Hypotheses; 2004; 63(5):917-8. PubMed ID: 15488670
    [No Abstract]   [Full Text] [Related]  

  • 33. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
    Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
    Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The plasma levels of granulocyte-colony stimulating factor and granulocyte-macrophage colony stimulating factor in breast cancer patients].
    Ławicki S; Czygier M; Omyła J; Bedkowska E; Szmitkowski M
    Pol Merkur Lekarski; 2007 Oct; 23(136):259-63. PubMed ID: 18293847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The CA-125 tumor marker in epithelial ovarian cancers of stage I].
    Nagele F; Vavra N; Kurz C; Sevelda P
    Wien Klin Wochenschr; 1993; 105(20):585-8. PubMed ID: 8259686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Macrophage colony-stimulating factor for treatment of prostatic cancer with bone metastases].
    Hayashi T; Kakehi R
    Hinyokika Kiyo; 1993 Jan; 39(1):101-5. PubMed ID: 8460579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic markers for early detection of ovarian cancer.
    Visintin I; Feng Z; Longton G; Ward DC; Alvero AB; Lai Y; Tenthorey J; Leiser A; Flores-Saaib R; Yu H; Azori M; Rutherford T; Schwartz PE; Mor G
    Clin Cancer Res; 2008 Feb; 14(4):1065-72. PubMed ID: 18258665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum follicle-stimulating hormone and risk of epithelial ovarian cancer in postmenopausal women.
    Arslan AA; Zeleniuch-Jacquotte A; Lundin E; Micheli A; Lukanova A; Afanasyeva Y; Lenner P; Krogh V; Muti P; Rinaldi S; Kaaks R; Berrino F; Hallmans G; Toniolo P
    Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1531-5. PubMed ID: 14693749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic markers for ovarian cancer screening: not ready for routine clinical use.
    Coates RJ; Kolor K; Stewart SL; Richardson LC
    Clin Cancer Res; 2008 Nov; 14(22):7575-6; author reply 7577-9. PubMed ID: 18948387
    [No Abstract]   [Full Text] [Related]  

  • 40. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
    Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
    Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.